Abstract
Ventricular arrhythmias are common in the setting of acute myocardial infarction (AMI). In todays era of reperfusion therapy, anti-arrhythmic medications, and Implantable Cardioverter Defibrillators (ICDs), an understanding of these arrhythmias and the prognosis of patients with these arrhythmias is essential in determining the proper treatment strategy. In general, ventricular arrhythmias occurring in the first 48 hours (early) following admission for AMI do not predict an increased risk of arrhythmias in follow-up. While early sustained ventricular tachycardia and ventricular fibrillation predict increased in-hospital mortality, the medium and long-term mortality is comparable to control populations in most studies. In contrast, ventricular arrhythmias occurring after 48 hours (late) generally predict an increased risk of arrhythmias and sudden cardiac death. This review focuses on the different ventricular arrhythmias which occur in both the early and late stages following myocardial infarction. Special attention is made to the incidence and prognosis of these arrhythmias, and how this relates to current treatment recommendations.
Keywords: Ventricular tachycardia, ventricular fibrillation, myocardial infarction
Current Cardiology Reviews
Title: Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction
Volume: 3 Issue: 1
Author(s): Douglas W. Laidlaw, Munther K. Homoud, Jonathan Weinstock, N. A. Mark Estes III and Mark S. Link
Affiliation:
Keywords: Ventricular tachycardia, ventricular fibrillation, myocardial infarction
Abstract: Ventricular arrhythmias are common in the setting of acute myocardial infarction (AMI). In todays era of reperfusion therapy, anti-arrhythmic medications, and Implantable Cardioverter Defibrillators (ICDs), an understanding of these arrhythmias and the prognosis of patients with these arrhythmias is essential in determining the proper treatment strategy. In general, ventricular arrhythmias occurring in the first 48 hours (early) following admission for AMI do not predict an increased risk of arrhythmias in follow-up. While early sustained ventricular tachycardia and ventricular fibrillation predict increased in-hospital mortality, the medium and long-term mortality is comparable to control populations in most studies. In contrast, ventricular arrhythmias occurring after 48 hours (late) generally predict an increased risk of arrhythmias and sudden cardiac death. This review focuses on the different ventricular arrhythmias which occur in both the early and late stages following myocardial infarction. Special attention is made to the incidence and prognosis of these arrhythmias, and how this relates to current treatment recommendations.
Export Options
About this article
Cite this article as:
Laidlaw W. Douglas, Homoud K. Munther, Weinstock Jonathan, Mark Estes III A. N. and Link S. Mark, Prognosis and Treatment of Ventricular Arrhythmias Following Myocardial Infarction, Current Cardiology Reviews 2007; 3(1) . https://dx.doi.org/10.2174/157340307779940004
DOI https://dx.doi.org/10.2174/157340307779940004 |
Print ISSN 1573-403X |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6557 |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Colchicine: A Review on Chemical Structure and Clinical Usage
Infectious Disorders - Drug Targets Exosomes: The Messengers of Health and Disease
Current Neuropharmacology Green Synthesis of Zinc Oxide Nanoparticles (ZnO NPs) using Aqueous Extract of <i>Tagetes Erecta</i> flower and Evaluation of its Antioxidant, Antimicrobial, and Cytotoxic activities on HeLa cell line.
Current Biotechnology Developing Stress Assessment forms for Thai Cancer Patients: The Thai Version of the Modified Symptoms of Stress Inventory (Modified SOSI)
Current Psychiatry Research and Reviews Application of Carbon Nanotubes In Drug Delivery of Non-cancerous Diseases: A Review
Current Pharmaceutical Design The Role of Apelins in the Physiology of the Heart
Protein & Peptide Letters Co-medications and Drug-Drug Interactions in People Living with HIV in Turkey in the Era of Integrase Inhibitors
Current HIV Research Metabolic Obesity: The Paradox Between Visceral and Subcutaneous Fat
Current Diabetes Reviews Drug-Induced Thromboembolic Events in Patients with Malignancy
Cardiovascular & Hematological Disorders-Drug Targets VIP in Inflammatory Bowel Disease: State of the Art
Endocrine, Metabolic & Immune Disorders - Drug Targets Antioxidant Therapy Against Trypanosome Infections: A Review Update
Current Topics in Medicinal Chemistry Multi-Constituent Cardiovascular Pills (MCCP) - Challenges and Promises of Population-Based Prophylactic Drug Therapy for Prevention of Heart Attack
Current Pharmaceutical Design The Role of Brain Gaseous Transmitters in the Regulation of the Circulatory System
Current Pharmaceutical Biotechnology Novel Approaches to Study the Involvement of α7-nAChR in Human Diseases
Current Drug Targets Mevalonate Pathway and Human Cancers
Current Molecular Pharmacology Editorial [Hot Topic: Novel Pharmacological Therapies for Cardiac Hypertrophy and Heart Failure (Executive Guest Editor: Peter M. Kang)]
Current Pharmaceutical Design Pharmacological Interference With Protein-protein Interactions of Akinase Anchoring Proteins as a Strategy for the Treatment of Disease
Current Drug Targets Rational Autologous Cell Sources For Therapy of Heart Failure - Vehicles and Targets For Gene and RNA Therapies
Current Gene Therapy Simvastatin: Review of Updates on Recent Trends in Pharmacokinetics, Pharmacodynamics, Drug–drug Interaction, Impurities and Analytical Methods
Current Pharmaceutical Analysis Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design